Judging from its top line, AstraZeneca had a stellar 2024, generating an 18% increase in revenue, with 14 of the products in ...

In a report released today, James Gordon from J.P. Morgan maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target ...

In a phase 2 study, the company's medication suzetrigine barely performed better than a placebo in treating painful ...

AstraZeneca AZN stock has declined 14% in the past three months. A lot of this price decline is due to ongoing investigations at its China subsidiary. However, the overall drug and biotech sector ...

UBS Group upgraded shares of AstraZeneca (NASDAQ:AZN – Free Report) from a neutral rating to a buy rating in a research note ...

AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.

AstraZeneca PLC (LON:AZN – Get Free Report) shares passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of £114.82 ($144.52) and traded as high as ...

AstraZeneca’s share price has dropped recently on concerns relating to its Chinese operation, but this may have left the ...

A class action lawsuit was filed against AstraZeneca Plc (AZN) by Levi & Korsinsky on December 23, 2024. The plaintiffs ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

AstraZeneca's improving financial position isn't yet fully reflected in its stock price AstraZeneca's revenue was about $13.57 billion in the third quarter of 2024, up 18.1% year-over-year and 4. ...